Snapshot as of end 2024
The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development. We collaborate with public sector and industry partners to translate groundbreaking scientific discoveries into valuable biotherapeutic candidates.
Little Drug, Big Hope
Pipeline
EDDC aims to develop innovative therapeutics and companion diagnostics that have the potential to improve and save the lives of patients in Singapore and beyond. We want to advance the development of safe and effective therapies that address unmet medical needs.
We welcome partnerships with collaborators who share our vision, to jointly accelerate the development of our pipeline assets.
Find Out More About Drug Discovery
Playlist
Newsroom
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Recent News
Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma
Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer
EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours
Partner with Us
EDDC is equipped with comprehensive capabilities for advancing the discovery and development of small molecule or antibody-based drugs, as well as companion diagnostics.
As a publicly-funded researcher, you can benefit from our extensive expertise and capabilities to advance your drug discovery project in various ways.
Consultancy
Services